Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug levels and anti-drug antibodies to predict response in IBD
2011-006084-22Phase 4Unknown
- Sponsor
- Royal Liverpool University Hospital
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab and adalimumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Royal Liverpool University Hospital. Primary endpoint: Threshold concentration of anti-TNF agents for predicting remission. Status: unknown.
02
Drugs
infliximabadalimumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2011-006084-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006084-22.